Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1-Infected, Treatment-Experienced Patients

BACKGROUND: Vicriviroc, an investigational CCR5 antagonist, demonstrated short-term safety and antiretroviral activity. METHODS: Phase 2, double-blind, randomized study of vicriviroc in treatment-experienced subjects with CCR5-using HIV-1. Vicriviroc (5, 10 or 15 mg) or placebo was added to a failin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wilkin, Timothy J., Su, Zhaohui, Krambrink, Amy, Long, Jianmin, Greaves, Wayne, Gross, Robert, Hughes, Michael D., Flexner, Charles, Skolnik, Paul R., Coakley, Eoin, Godfrey, Catherine, Hirsch, Martin, Kuritzkes, Daniel R., Gulick, Roy M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917795/
https://ncbi.nlm.nih.gov/pubmed/20672447
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados